Wednesday, November 14th, 2018

 

Next
A full text version of this article is available.
To access article obtain online access here or login
 
Title:
Schlafen 11 Assessment in High-Grade Serous Ovarian Carcinoma: Phenotypic and Histologica Distribution
Authors:  Domenico Ferraioli, M.D., Leonardo Peñuela, M.D., Ph.D., Anna Garuti, M.Sc., Chiara Carrozzi, M.D., Timothee Olivier, M.D., Bruno Spina, M.D., Sandra Salvi, M.Sc., Simone Ferrero, Ph.D., Jean-Christophe Tille, M.D., Sana Intidhar Labidi-Galy, M.D., Gabriella Cirmena, M.D., Alberto Ballestero, M.D., Nicolas Chopin, M.D., Frederic Beurrier, M.D., Isabelle Treilleux, M.D., Isabelle Ray-Coquard, Ph.D., Gabriele Zoppoli, M.D., Ph.D., and Valerio Gaetano Vellone, M.D., Ph.D.
  Objective: To develop a protocol for immunohistochemistry (IHC) to determine the Schlafen 11 (SLFN11) expression in formalin-fixed, paraffin-embedded (FFPE) high-grade serous ovarian carcinoma (HGSOC) samples.
Study Design:
We validated a reliable SLFN11 antibody (SLFN11-Ab) in IHC choosing between 2 antiSLFN11-Abs used for western blot through the development of a SLFN11-IHC protocol in culture cell block (CCB) of ovarian carcinoma and in an HGSOC tissue microarray (TMA) series. We applied our protocol to a case series of HGSOC samples to confirm our preliminary results. For each case we evaluated both the intensity score (IS) and the distribution score (DS). A final histological score (HS) was obtained as follows: HS=IS×DS.
Results:
In CCB and TMA series, the antibody #1 at 1:100 dilution was more reliable. This last one was used in our case series to confirm our IHC protocol. DS showed the following results: 27 cases were no stain, 11 cases showed staining for SLFN11 in <10% of cells, 16 cases showed staining in 10–40% of cells, and the remaining 15 cases showed stain in >40% of cells. IS showed the following results: 25 cases were no stain, in 19 cases a dominant weak stain, in 14 cases a moderate stain, and in 11 cases a strong stain. HS for SLFN11 expression presents a normal distribution with a prevalent (≈60%) intermediate expression.
Conclusion:
We develop a reproducible and standardized IHC protocol to determinate the SLFN11 expression in FFPE HGSOC samples using a modified western blot anti-SLFN11-Ab.
Keywords:  anti-SLFN11 antibody, histological score, immunohistochemistry, ovarian cancer, ovarian neoplasms, Schlafen-11, SLFN11, serous high grade ovarian cancer
   
   
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from